Heparin-induced thrombocytopenia in 2017 and beyond

• References

• 1 Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998; 79: 1-7.
• 2 Warkentin TE, Greinacher A, Gruel Y. et al. Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. J Thromb Haemost 2011; 09: 2498-2500.
• 3 Delcea M, Greinacher A. Biophysical tools to assess the interaction of PF4 with polyanions. Thromb Haemost 2016; 116: 783-791.
• 4 Khandelwal S, Arepally GM. Immune pathogenesis of HIT. Thromb Haemost 2016; 116: 792-798.
• 5 Rollin J, Pouplard C, Gruel Y. Risk factors for he-parin-induced thrombocytopenia: focus on Fcγ receptors. Thromb Haemost 2016; 116: 799-805.
• 6 Madeeva D, Cines D, Poncz M, Rauova L. Role of monocytes and endothelial cells in heparin-induced thrombocytopenia. Thromb Haemost 2016; 116: 806-812.
• 7 Warkentin TE. Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia. Thromb Haemost 2016; 116: 813-822.
• 8 Nagler M, Bakchoul T. Clinical and laboratory tests for the diagnosis of heparin-induced throm-bocytopenia. Thromb Haemost 2016; 116: 823-834.
• 9 Cuker A. Management of the multiple phases of heparin-induced thrombocytopenia. Thromb Haemost 2016; 116: 835-842.
• 10 Selleng S, Selleng K. Heparin-induced thrombocytopenia in cardiac surgery and critically ill patients. Thromb Haemost 2016; 116: 843-851.